Financial Shenanigans

The Forensic Verdict

DAQO's reported numbers look broadly anchored in audited statements, but the forensic risk is Elevated at 54/100. The top concerns are cash-flow presentation around bank acceptance notes and a revenue/collection profile where FY2025 notes receivable rose sharply while revenue declined. The cleanest offsetting evidence is that the FY2025 Form 20-F has an unqualified audit opinion, an effective internal-control opinion, no error-correction restatement checkbox, advance-payment language for substantially all sales, and low goodwill/intangible exposure. The one data point that would most change the grade is whether FY2026 operating cash flow remains positive after notes payable and notes receivable normalize without new allowance or write-off pressure.

The 3-year CFO to net income ratio is mathematically distorted because 2023-2025 consolidated net income sums to a small loss of $11.4 million while CFO sums to $1.23 billion. The useful read-through is not the ratio itself; it is the reversal from strong 2023 collections to FY2024 cash burn and FY2025 cash flow that relied partly on non-cash charges and bank-note working capital.

Breeding Ground

The governance setting amplifies accounting risk modestly because founder-family influence and related-party history are real, while the current audit committee, audit opinion, and internal-control opinion dampen the risk.

CEO Xiang Xu is also chairman, founder Guangfu Xu remains a director, Xiaoyu Xu is deputy CEO and director, and directors and executives owned 36.1% of ordinary shares as of March 31, 2026. The audit committee is a strong offset: it is fully independent, chaired by Arthur Wong, and includes an audit committee financial expert. The company disclosed historical material weaknesses in 2011, including related-party controls, but states they no longer existed from 2013 through 2025 and management concluded FY2025 ICFR was effective.

Compensation disclosure is not granular because DAQO is a foreign private issuer: it reports $4.4M aggregate cash paid to directors and executives, not U.S.-style named executive officer tables. The share plans are worth monitoring because option exercise prices may be amended or adjusted under plan language, and share-based compensation remains material to adjusted results. Related-party transactions in FY2025 were small in dollars, but the broader Daqo Group history matters: the company discloses Daqo Group affiliations, non-competition arrangements, audit committee review for related-party transactions, and consent for Daqo Group to enter photovoltaic cell manufacturing.

Earnings Quality

Earnings quality is strained by the polysilicon downturn, not by a single obvious revenue manipulation pattern; the main accounting tests are cut-off, notes receivable, reserves, and the timing of write-downs.

Revenue fell 35.3% in FY2025, but notes receivable increased 145.7%. That is not automatically a revenue-recognition failure because notes receivable are bank acceptance drafts and the company says substantially all sales require advance payments before shipment. It still raises collection-quality risk because Deloitte separately identified revenue cut-off for domestic polysilicon sales as a critical audit matter, and FY2025 DSO rose to 52.3 days from 30.4 days.

Inventory days also rose to 72.5 in FY2025 as utilization stayed low, while DPO rose to 37.0. The pattern is consistent with a cyclical producer managing through oversupply, but it makes the balance sheet less clean than the income statement alone suggests.

The big-bath test is a yellow flag, not a conclusion. FY2024 included $175.6M of long-lived asset impairment and $81.4M of inventory write-downs, both consistent with prices falling below cost. FY2025 then had no long-lived asset impairment despite a still-negative 20.7% gross margin, while allowance for expected credit loss increased again. The clean test is that returns were not material and the company discloses no warranties, incentives, or rebate arrangements offered to customers.

Cash Flow Quality

Cash flow quality is the weakest part of the file: FY2025 CFO turned positive, but free cash flow remained negative and the bridge depended on non-cash charges plus bank-note working capital.

Over the last three fiscal years, CFO was positive $1.23B while FCF was negative $412.3M and consolidated net income was close to break-even. That mix is not a fraud signal by itself in a capex-heavy commodity business, but it says valuation should not capitalize CFO as though it were recurring free cash generation.

The core mechanism in FY2025 is visible. Notes payable contributed $98.8M of operating cash flow, more than total FY2025 CFO of $49.7M, while notes receivable used $76.3M and inventory used $34.3M. The filing says notes payable are bank-issued supplier notes that extend payment terms and do not represent cash borrowings because they are repaid using restricted cash and deposits at the same banks. That disclosure is useful, but it also means CFO is sensitive to the bank-note cycle.

Metric Hygiene

Management's preferred metrics are reconciled, but the recurring share-based compensation add-back, EBITDA emphasis, and liquidity framing can overstate the speed of recovery.

The non-GAAP issue is not definition drift; it is economic weight. Adjusted net loss excludes only share-based compensation in the reviewed reconciliation, which is transparent, but the add-back is large relative to current revenue and appears every year. EBITDA is also heavily influenced by depreciation in a newly expanded, underutilized asset base.

What to Underwrite Next

The next underwriting work should focus on whether the FY2025 cash-flow bridge converts into cash earnings, or whether receivables, notes payable, and write-downs keep rotating through the statements.

This forensic work should be a valuation haircut and position-sizing limiter, not a thesis breaker on the present evidence. The audited statements have meaningful clean offsets, but FY2025 cash generation is not strong enough to underwrite at face value because bank-note mechanics, receivable conversion, negative FCF, and recurring add-backs still matter. A larger margin of safety is warranted until the company shows cash earnings without notes-payable support and without another reserve or impairment cycle.